siltuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 4977 541502-14-1

Description:

MoleculeDescription

Synonyms:

  • siltuximab
  • sylvant
  • CNTO-328
  • CNTO 328
a chimeric anti-interleukin-6 antibody for treatment of multiple myeloma and renal cell carcinoma; in phase I and phase II clinical trials. It was investigated for its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 but the efficacy and safety of siltuximab in the treatment of COVID-19 were not established.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
37 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 22, 2014 EMA
April 23, 2014 FDA JANSSEN BIOTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune effector cell-associated neurotoxicity syndrome 82.36 67.10 13 230 2264 63486515

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune effector cell-associated neurotoxicity syndrome 93.82 74.95 17 334 5831 79738206

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC11 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000191004 Interleukin-6 Antagonists
FDA EPC N0000191006 Interleukin-6 Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Castleman's disease indication 207036003 DOID:0111157




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-6 Cytokine ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
T4H8FMA7IM UNII
D09669 KEGG_DRUG
4033374 VUID
N0000190760 NUI
4033374 VANDF
C1609931 UMLSCUI
CHEMBL1743070 ChEMBL_ID
DB09036 DRUGBANK_ID
9051 INN_ID
C504234 MESH_SUPPLEMENTAL_RECORD_UI
7396 IUPHAR_LIGAND_ID
1535218 RXNORM
219193 MMSL
30272 MMSL
d08253 MMSL
015497 NDDF
704262001 SNOMEDCT_US
704263006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sylvant HUMAN PRESCRIPTION DRUG LABEL 1 73090-420 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAVENOUS BLA 31 sections
Sylvant HUMAN PRESCRIPTION DRUG LABEL 1 73090-420 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAVENOUS BLA 31 sections
Sylvant HUMAN PRESCRIPTION DRUG LABEL 1 73090-421 INJECTION, POWDER, FOR SOLUTION 400 mg INTRAVENOUS BLA 31 sections
Sylvant HUMAN PRESCRIPTION DRUG LABEL 1 73090-421 INJECTION, POWDER, FOR SOLUTION 400 mg INTRAVENOUS BLA 31 sections